2014年7月30日訊 /生物谷BIOON/--曼徹斯特的科學家發現了一種蛋白質，可以幫助醫生確定哪些膀胱癌患者將受益於治療，研究結果發表在英國癌症雜誌（BJC）雜誌上。
來自曼徹斯特大學的團隊發現膀胱腫瘤患者有較高水平的蛋白質HIF-1α，更有可能受益於一種治療方法，即在放療的同時給予患者混和氧（95％O2、5％CO2的混合氣體）和煙醯胺片。這種治療方法被稱為「CON」，能使放射放療更有效。
通過比較，單獨放療或放療與CON聯合治療患者腫瘤組織樣本中HIF-1α的水平，研究人員發現該蛋白能預測哪些患者受益於CON。當患者接受放療和CON，高濃度的蛋白質與疾病更好的生存有關聯。低蛋白水平患者並沒有受益於CON與組合放射治療。 （生物谷Bioon.com）
Expression hypoxia-inducible factor-1α predicts benefit from hypoxia modification in invasive bladder cancer
Hunter, BA et al.
Background:
The addition of carbogen and nicotinamide (CON) to radiotherapy (RT) improves overall survival in invasive bladder cancer. We explored whether expression of the hypoxia marker hypoxia-inducible factor-1α (HIF-1α) alone or in combination with other markers predicted benefit from CON.
Methods:
A retrospective study was carried out using material from patients with high-grade invasive bladder carcinoma enrolled in the BCON phase III trial of RT alone or with CON (RT+CON). HIF-1α expression was studied in 137 tumours using tissue microarrays and immunohistochemistry. Data were available from other studies for carbonic anhydrase IX and glucose transporter 1 protein and gene expression and tumour necrosis.
Results:
Patients with high HIF-1α expression had improved 5-year local relapse-free survival with RT+CON (47%) compared with RT alone (21%; hazard ratio (HR) 0.48, 95% CI 0.26–0.8, P=0.02), no benefit was seen with low HIF-1α expression (HR 0.81, 95% CI 0.43–1.50, P=0.5). Combinations of markers including necrosis also predicted benefit but did not improve on prediction using necrosis alone.
Conclusions:
HIF-1α may be used to predict benefit from CON in patients with bladder cancer but does not improve on use of necrosis.